Dual immune checkpoint inhibition in advanced incurable radioidine-refractory differentiated thyroid carcinoma (RAIR DTC), anaplastic (ATC), and medullary thyroid carcinoma (MTC): Long-term survival results from phase II clinical trial.

Authors: Kartik Sehgal, Theodora Pappa, Kee-Young Shin, Mofei Liu, Kathleen L. Pfaff, Justine A. Barletta, Gerard M. Doherty, Erik K. Alexander, Scott Rodig, Glenn J. Hanna, David Allen Barbie, Anne ONeill, Eliezer Mendel Van Allen, Robert I. Haddad, Jochen H. Lorch

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.6105

Source: Full article

---

Abstract

6105